Prøve GULL - Gratis

Ayurveda gaining significant traction in global markets

Chronicle Pharmabiz

|

November 27, 2025

DRIVEN by the growing demand for natural and holistic wellness products, Ayurveda is gaining significant traction in international markets.

- Our Bureaus, Bengaluru, New Delhi

Ayurveda gaining significant traction in global markets

The global Ayurveda market is estimated to be billions of dollars, with forecasts predicting strong double-digit growth over the coming decade.

One of the key drivers fuelling this growth is the increasing popularity of natural products. Consumers are seeking alternative, plant-based remedies, driving demand for Ayurvedic products. The Indian government is also promoting Ayurveda through a number of initiatives Moreover India's “Heal in India” initiative aims to integrate modern medicine with Ayurveda, attracting international patients.

To capitalize on this trend, Indian Ayurvedic companies are focusing on sustainable practices, organic sourcing, and eco-friendly packaging.

Growing awareness of herbal products

According to Dr DBA Narayana, CSO, Ayurvidye Trust, with many efforts by the Ayush Ministry and Government of India during and post Covid, there has been growing awareness and some acceptance for herbal based products including Ayurvedic products. However, one facet of this globally has not been extended and used to promote exports of ayurvedic medicines and products.

Qualified ayurvedic clinicians should consider using technology to make such video consultation possible, they need to identify simple classical medicines that can be recommended to the patients who consult them. Ayush Ministry should make list of Classical grantha preparation which have a high safety profile and liase with governments globally to initiate a process for" import of such medicines prescribed for personal use n some simple import regulations in that country that permit importation for personal use”, said Dr Narayana.

FLERE HISTORIER FRA Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size